Clinical Trials

The purpose of this study is to determine the effectiveness and safety of aPCC FEIBA in children undergoing cardiac surgery with cardiopulmonary bypass.

The purpose of this study is to determine if the medication, sildenafil (also known as Revatio), can slow or stop the progression of liver disease in patients who previously had a Fontan operation.

The purpose of this study is to evaluate how children and young adults perceive their midline sternotomy scars (in terms of appearance, associated symptoms, consciousness, satisfaction with appearance/symptoms, and impact on quality of life)? 

The purpose of the study is to determine the outcome of surgical intervention versus observation in children and young adults with AAOCA. To do this the plan is to create a registry of AAOCA subjects that will enable us to develop a risk stratification model utilizing a large multi-institutional registry under the auspices of the Congenital Heart Surgeons’ Society (CHSS).

The purpose of this initiative is to improve care and outcomes for infants with HLHS by expanding the NPC-QIC national registry to gather clinical care process, outcome, and developmental data on infants with HLHS between diagnosis and 12 months of age, by improving the use of standards into everyday practice across pediatric cardiology centers, and by engaging parents as partners in the process.

The purpose of this study is to see whether advice by clinicians to cigarette smokers who are parents of children undergoing elective surgery can reduce the exposure of these children to secondhand smoke in the time around surgery.    
 

To demonstrate the proof of principle and initial clinical safety of the CorMatrix ECM Tricuspid Valve and increase the efficiency of the device development process by identifying appropriate modifications to the implant procedure or the device.

This study aims to evaluate the safety of intramyocardial delivery of autologous umbilical cord blood-derived mononuclear cells during Fontan surgical palliation and measure surrogate markers of myocardial protection within a non-randomized study design to obtain prospective data from treatment and control populations.